[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@d_stock07734 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1660707117722902539.png) @d_stock07734 d_stock

d_stock posts on X about $nwbo, investment, $rvmd, drivers the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1660707117722902539/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1660707117722902539/c:line/m:interactions.svg)

- X Week XXXXXX +357%
- X Month XXXXXX +35%
- X Months XXXXXXX +234%
- X Year XXXXXXX +99%

### Mentions: XX [#](/creator/twitter::1660707117722902539/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1660707117722902539/c:line/m:posts_active.svg)

- X Week XX +58%
- X Month XX +10%
- X Months XXX +212%
- X Year XXX +131%

### Followers: XXX [#](/creator/twitter::1660707117722902539/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1660707117722902539/c:line/m:followers.svg)

- X Week XXX +1%
- X Month XXX +2.80%
- X Months XXX +7.30%
- X Year XXX -XX%

### CreatorRank: XXXXXXX [#](/creator/twitter::1660707117722902539/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1660707117722902539/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1660707117722902539/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [finance](/list/finance)  XXXX% [currencies](/list/currencies)  XXXX%

**Social topic influence**
[$nwbo](/topic/$nwbo) #3, [investment](/topic/investment) 3.41%, [$rvmd](/topic/$rvmd) #3, [drivers](/topic/drivers) 2.27%, [has been](/topic/has-been) 2.27%, [$8750t](/topic/$8750t) #6, [$mrk](/topic/$mrk) #15, [$nwbos](/topic/$nwbos) 1.14%, [number of](/topic/number-of) 1.14%, [long term](/topic/long-term) XXXX%

**Top accounts mentioned or mentioned by**
[@mdendream](/creator/undefined) [@maveric92283613](/creator/undefined) [@dcvaxdefender](/creator/undefined) [@dcvaxcohenm](/creator/undefined) [@rbioceutics](/creator/undefined) [@andrewcaravello](/creator/undefined) [@flemmingbruce](/creator/undefined) [@jascanlan](/creator/undefined) [@mazzulolorie](/creator/undefined) [@philburginvests](/creator/undefined) [@dstock07734](/creator/undefined) [@calilerone](/creator/undefined) [@justinkeister5](/creator/undefined) [@flyfishing15331](/creator/undefined) [@hoffmann6383](/creator/undefined) [@mittypost](/creator/undefined) [@smith348572](/creator/undefined) [@michael48826289](/creator/undefined) [@biotech2k1](/creator/undefined) [@alphavestcap](/creator/undefined)

**Top assets mentioned**
[Revolution Medicines, Inc. Common Stock (RVMD)](/topic/$rvmd) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [uniQure N.V. (QURE)](/topic/$qure)
### Top Social Posts [#](/creator/twitter::1660707117722902539/posts)
---
Top posts by engagements in the last XX hours

"$NWBO It seems like Merck is going to file the approval of oral PCSK9 inhibitor (MK-0616) as the treatment for hypercholesterolemia. No doubt Merck knows that MK-0616 can be used for cancer treatment and it is among XX new growth drivers that have blockbuster potential. DoD (W81XWH-21-1-0532) once sponsored a trial on using Amgen's PCSK9 inhibitor (Evolocumab) in combination with BMS's two checking point inhibitors to treat lung cancer. Dr. Scott Antonia was the PI of the trial. Regeneron also sponsored a trial similar to the above one and the combination adopted in the trial is Regneron's"  
[X Link](https://x.com/d_stock07734/status/1976146499659518445) [@d_stock07734](/creator/x/d_stock07734) 2025-10-09T04:43Z XXX followers, XXX engagements


"Analysis of this nature has been done millions of times. It's useless. Can we discuss how revolutionary $NWBO's DC technology is The efficacy of DC vaccine largely depends on the number of tumor antigens DCs can present to immune system. How many can Provenge present Just one specific tumor antigen. Read the PR and tell me the number of tumor antigens NWBO's DC technology can make DCs present"  
[X Link](https://x.com/d_stock07734/status/1978883611756532151) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T17:59Z XXX followers, XXX engagements


"$NWBO It's interesting that Roche sponsored a trial on using the combination of XCR1 with DC vaccine and Atezolizumab (PD-L1 inhibitor) to treat late stage small cell lung cancer. Among XX patients enrolled XX% are PD-L1 negative. The results were presented one year ago. There will be a presentation on this trial next week. Long term survivors from Phase Ib-II trial of tumor-loaded monocyte-derived dendritic cell vaccination plus atezolizumab in ES-SCLC Not sure if the research institution at Spain is involved in the symphony. But it's good to see Roche has interest in DC vaccine therapy."  
[X Link](https://x.com/d_stock07734/status/1978925646622458197) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T20:46Z XXX followers, 4060 engagements


"You guys still think about BO. Merck acquired Verona and Prometheus. The presentations can provide the hints on how Merck prices a BO target. Can Merck do the same for NWBO Take a closer look at the lead candidates from the two companies to see if they can be something complementary to or synergistic with DCVax. Ohtuvayre a dual PDE3 and PDE4 inhibitor from Verona can be used to overcome immunosuppression due to tumor-associated neutrophils. When DCs loaded with tumor-associated peptides migrate to lymph nodes they want to contact t-cells as many as possible. That's why IL-2 from Prometheus"  
[X Link](https://x.com/d_stock07734/status/1976877785571320095) [@d_stock07734](/creator/x/d_stock07734) 2025-10-11T05:09Z XXX followers, XXX engagements


"What would happen to the sp if Merck could front $NWBO over at least $10b for collaborations on combining its over XX new growth drivers with DCVax What would happen to the sp if Baker Brothers could make a big investment in $NWBO Amgen acquired Horizon $28b in cash and its Actimmune cannot bring big revenue unless it can be combined with the Direct. All the combinations Dr. Bosch showed in the presentation had 'I' which most likely stands for Interferon Gamma-1b (ACTIMMUNE)"  
[X Link](https://x.com/d_stock07734/status/1977041389541073246) [@d_stock07734](/creator/x/d_stock07734) 2025-10-11T15:59Z XXX followers, 3617 engagements


"A collaboration trial between Merck and TILT Biotherapeutics on ovarian cancer. One of the conclusions is that Median progression-free survival and overall survival were XX and XXX days respectively. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (PROTA) The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial"  
[X Link](https://x.com/d_stock07734/status/1977604460680532234) [@d_stock07734](/creator/x/d_stock07734) 2025-10-13T05:17Z XXX followers, XXX engagements


"@mazzulo_lorie @andrewcaravello Did you see how Merck set up and acquired Immune Design I was wondering if Merck was trying to do the same on $NWBO. But Merck didn't make it"  
[X Link](https://x.com/d_stock07734/status/1978690142643560870) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T05:11Z XXX followers, XXX engagements


"$NWBO Going through the products from some BPs and wondering if those products can be combined with DCVax to treat cancer is really a wonderful experience. ACTIMMUNE (interferon gamma-1b): No need to explain this one. Aimovig (erenumab-aooe) is a CGRP inhiibtor: The inhibition of CGRP may lead to an increase in the DC's antigen-presenting capacity potentially boosting T-cell activation. By blocking CGRP's suppressive effects CGRP inhibitors can allow for greater DC activation and higher production of pro-inflammatory cytokines like TNF- which CGRP normally represses. Blocking CGRP's influence"  
[X Link](https://x.com/d_stock07734/status/1978845732179251457) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T15:29Z XXX followers, 3296 engagements


"$NWBO ESMO 2025 preview Merck hopes for Daiichi redemption Did Merck strike the deal with Daiichi after Merck replaced BMS as the sponsor for the SPORE project Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit"  
[X Link](https://x.com/d_stock07734/status/1979294597751722147) [@d_stock07734](/creator/x/d_stock07734) 2025-10-17T21:13Z XXX followers, XXX engagements


"The bidding war makes our shares more valuable. Here is what LP said at ASM on June XX 2024. But we have said in every presentation we are eager to combine DCVax-L with these other combinations. And so one of our many priorities for the going forward period is to do one or more of those combinations. And we've received considerable interest from various parties for that. So we are looking forward to that. One thing I will say about our general approach as we look forward on further clinical trials is this: We want to focus particularly on clinical trials where tumor response meaning tumor"  
[X Link](https://x.com/d_stock07734/status/1979778533468557538) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T05:15Z XXX followers, XX engagements


"$NWBO It's so obvious that DCVax in combination with PD-1 / VEGF Bispecific should deliver much better results than PD-1 inhibitor in cancer treatment. Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by XX% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Is there significant difference between Tislelizumab and Pembrolizumab in terms of efficacy Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced"  
[X Link](https://x.com/d_stock07734/status/1980024182558589340) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T21:32Z XXX followers, XXX engagements


"@Biotech2k1 @hbnewone Both Merck and BMS signed the deals on PD1/VEGF Bispecific. If someone wants to buy $SMMT the price should be pretty high"  
[X Link](https://x.com/d_stock07734/status/1980038879509090518) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T22:30Z XXX followers, XXX engagements


"$NWBO @Rainmaker1973 cannot answer the question and blocked me"  
[X Link](https://x.com/d_stock07734/status/1977033186749345951) [@d_stock07734](/creator/x/d_stock07734) 2025-10-11T15:26Z XXX followers, 2568 engagements


"$NWBO Don't forget about this one. Is it possible that Imiquimod (TLR7) has been included in the UK Specials Program too DCVax-L + Poly-ICLC (TLR3) DCVax-L + Imiquimod (TLR7) Study Start: 2003-06 Primary Completion (Actual): 2012-09 Study Completion (Actual): 2012-09"  
[X Link](https://x.com/d_stock07734/status/1978536941311111305) [@d_stock07734](/creator/x/d_stock07734) 2025-10-15T19:02Z XXX followers, 4603 engagements


"@mazzulo_lorie @andrewcaravello Why would he leave for Regeneron as an associate director on field medical affairs Why did Roger Perlmutter take the CEO job of a startup one week after stepping down from Merck Did Merck place most of its $40b strategic investment after Perlmutter left"  
[X Link](https://x.com/d_stock07734/status/1978582037888909552) [@d_stock07734](/creator/x/d_stock07734) 2025-10-15T22:01Z XXX followers, XXX engagements


"$NWBO Dr. Liau provided the map for treasure hunt The longs should use it"  
[X Link](https://x.com/d_stock07734/status/1978870569996034160) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T17:08Z XXX followers, 2155 engagements


"$NWBO NIH Leaders Fired CDC Gets Acting Center Directors and Prasad Shapes FDA Team"  
[X Link](https://x.com/d_stock07734/status/1976368815131820437) [@d_stock07734](/creator/x/d_stock07734) 2025-10-09T19:26Z XXX followers, 1058 engagements


"$NWBO Anthony Wang gave a presentation on early findings of the trial on using DCs loaded with peptides derived from H3 G34 to treat DHG. Systemic oligoclonal anti-tumor cytotoxic T cell response was observed in the trial. Recall what happened to the combo trial after keytruda was added to the combination of DCVax-L plus poly-iclc. No doubt adding two checking point inhibitors Nivolumab and Ipilimumab to the current combination in treating DHG should deliver blockbuster results. Clearly Merck would not let this trial proceed. A systemic oligoclonal anti-tumor cytotoxic T cell response is a"  
[X Link](https://x.com/d_stock07734/status/1977925855734358331) [@d_stock07734](/creator/x/d_stock07734) 2025-10-14T02:34Z XXX followers, 3613 engagements


"$NWBO BPs are interested in using DCs to treat autoimmune diseases. They fronted hundreds of millions of dollars for a company which has not started a clinical trial yet. The interesting part is that EVOQ Therapeutics used to include cancer in its pipeline on its webpage and remove it in 2021. In terms of using DC vaccine technology to treat solid tumor it's LP's domain totally Sanofi inks $500M deal with Evoq for next-gen autoimmune tech Gilead hopes to evoke ideas for new autoimmune treatments with $659M deal Evoq pens $240M Amgen pact for next-gen autoimmune meds EVOQ Therapeutics and"  
[X Link](https://x.com/d_stock07734/status/1978896455801721171) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T18:50Z XXX followers, 2513 engagements


"$NWBO The Academy of Immuno-Oncology was established by SITC to honor individuals who have launched the field of cancer immunotherapy into the breakthrough cancer treatment it is today and bring together the brightest minds in the field to continue to advance SITC the field and the next generation of immuno-oncologists"  
[X Link](https://x.com/d_stock07734/status/1978913259848896993) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T19:57Z XXX followers, 1637 engagements


"$NWBO The following trial conducted at Mayo Clinic already produced phenomenal results. Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer In the pilot study group X enrolled patients with unresectable intrahepatic cholangiocarcinoma (CCA) who received the treatment of External Beam Radiotherapy+ DC intratumorally + Prevnar XX. The phase II study was initiated in May 2023 which consists of two groups. Group I was enrolling the"  
[X Link](https://x.com/d_stock07734/status/1979243198733259130) [@d_stock07734](/creator/x/d_stock07734) 2025-10-17T17:48Z XXX followers, 2421 engagements


"$NWBO $RVMD is going to face competition from Incyte. INCB161734 (KRAS G12D) Preliminary Phase X Results Of INCB161734 A Novel Oral KRAS G12D Inhibitor In Patients With Advanced Or Metastatic Solid Tumors (Session Title: Proffered paper session: Developmental therapeutics. October XX 8:45 10:20 a.m. ET 2:45 4:20 p.m. CEST. Abstract #916O.)"  
[X Link](https://x.com/d_stock07734/status/1979292412758626542) [@d_stock07734](/creator/x/d_stock07734) 2025-10-17T21:04Z XXX followers, 2563 engagements


"$NWBO Maybe $RVMD is not going to face competition from Incyte since Baker Brothers own X% of $RVMD. MOONRAY-01 a phase X study of LY3962673 a potent orally bioavailable and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification HER2 mutation/amplification HER3/4 mutation or KRAS mutation Vivek Subbiah: Talk about shaking the field of cancer research- cracking KRAS"  
[X Link](https://x.com/d_stock07734/status/1979369099323953267) [@d_stock07734](/creator/x/d_stock07734) 2025-10-18T02:09Z XXX followers, 2150 engagements


"$NWBO From Dr. Timothy Cloughesy's slides"  
[X Link](https://x.com/d_stock07734/status/1979710811020095866) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T00:46Z XXX followers, 2950 engagements


"$NWBO Merck is going to have Q3 report the end of October. It will be interesting to see if Merck will mention about the XX new growth drivers again. Merck Q4 2024 Earnings In fact we have XX potential new growth drivers almost all of which have blockbuster opportunity. These include WINREVAIR and CAPVAXIVE our adult pneumococcal conjugate vaccine which is now launching in the U.S. as well as many innovative assets currently in Phase X development. Merck Q1 2025 Earnings Together our efforts have resulted in an expanded late-phase pipeline comprising programs having potential commercial"  
[X Link](https://x.com/d_stock07734/status/1979916738121658826) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T14:25Z XXX followers, 1618 engagements


"$NWBO Two trials on ovarian cancer. One is the collaboration trial between Merck and Daiichi on using ADC to treat the cancer. The other is about using FRalpha-loaded DC vaccine to treat the cancer. A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant High-grade Ovarian Primary Peritoneal or Fallopian Tube Cancer Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial Fallopian Tube or Primary Peritoneal Cavity Cancer Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients"  
[X Link](https://x.com/d_stock07734/status/1980671831892783158) [@d_stock07734](/creator/x/d_stock07734) 2025-10-21T16:25Z XXX followers, 1164 engagements


"What happened to the following trials Why did IBRX terminate the trials Can you list the percentage of the patients who had complete response Seems like you should worry about your investment in IBRX first. QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. QUILT-3.090: NANT Squamous"  
[X Link](https://x.com/d_stock07734/status/1980686009957282166) [@d_stock07734](/creator/x/d_stock07734) 2025-10-21T17:21Z XXX followers, XX engagements


"$NWBO Regeneron conducted a trial on using Garetosmab to get rid of Activin A protein related to an ultra-rare disease called Fibrodysplasia Ossificans Progressiva (FOP). Mutated genes related to the Activin A protein include ACVR1 ACVR2A and ACVR2B. Of course trials can be set up so that peptides derived from these three genes can be loaded on DCs to treat FOP. There could be one answer to many diseases Garetosmab is a monoclonal antibody that neutralizes the Activin A protein which Regeneron scientists discovered to be a critical protein in the development of HO lesions in people with FOP."  
[X Link](https://x.com/d_stock07734/status/1971293675834798407) [@d_stock07734](/creator/x/d_stock07734) 2025-09-25T19:20Z XXX followers, 4036 engagements


"$NWBO Roche's pipeline"  
[X Link](https://x.com/d_stock07734/status/1978888125616128116) [@d_stock07734](/creator/x/d_stock07734) 2025-10-16T18:17Z XXX followers, 1067 engagements


"$NWBO How many companies are there that can provide stimulatory factors and inhibitors that boost anti-tumor immune response"  
[X Link](https://x.com/d_stock07734/status/1979978742534422755) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T18:31Z XXX followers, 1060 engagements


"$NWBO These pneumococcal vaccines can trigger an antiviral immune response although it is not an antiviral vaccine. This effect is not due to direct viral immunity but results from complex interactions between bacteria and viruses in the respiratory tract. The vaccine primarily works by preventing pneumococcal disease and reducing bacterial carriage which in turn benefits the antiviral pathway. Pneumovax 23: A 23-valent pneumococcal polysaccharide vaccine for adults XX years of age and older. Capvaxive (PCV21): A 21-valent pneumococcal conjugate vaccine for adults XX years of age and older."  
[X Link](https://x.com/d_stock07734/status/1979981001364586547) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T18:40Z XXX followers, 2412 engagements


"$NWBO Some DC vaccine trials that had pneumococcal vaccine in the combination on treating cancer. The trial NCT00683241 was sponsored by $NWBO. A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer Last Update Posted 2013-02-26 Prevnar + DCVax-L + Bevacizumab (VEGF inhibitor) + Cyclophosphamide Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma Intratumoral DCs + pembrolizumab + Prevnar13 Dendritic Cell Therapy Cryosurgery and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Intratumoral DCs"  
[X Link](https://x.com/d_stock07734/status/1980037811555205152) [@d_stock07734](/creator/x/d_stock07734) 2025-10-19T22:26Z XXX followers, 2883 engagements


"$NWBO Incyte Announces Phase X Results for its TGFR2PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma At doses XXX mg qd (n=27) X pts (30%) had partial responses (PR) and XX pts (85%) had disease control (PR + stable disease); pts with PR included X with PDAC X CRC X ovarian and X CUP. Among pts with detectable G12D in plasma ctDNA XX% had early molecular response (90% reduction) including responders. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation"  
[X Link](https://x.com/d_stock07734/status/1980763203542855735) [@d_stock07734](/creator/x/d_stock07734) 2025-10-21T22:28Z XXX followers, XXX engagements